Yes, proliferative activity can be a predictor of clinical outcomes. High proliferative activity is generally associated with a worse prognosis, including a higher likelihood of recurrence and metastasis. Conversely, low proliferative activity often correlates with a better prognosis. This information is crucial for staging the cancer and predicting patient survival, helping to tailor follow-up and treatment strategies accordingly.
